The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
This transaction fundamentally strengthens Scinai's CDMO platform
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks
Subscribe To Our Newsletter & Stay Updated
